Targeted Proteomics Driven Verification of Biomarker Candidates
Associated with Breast Cancer Aggressiveness

C 2018

Targeted Proteomics Driven Verification of Biomarker Candidates Associated with Breast Cancer Aggressiveness

PROCHÁZKOVÁ, Iva; Juraj LENČO a Pavel BOUCHAL

Základní údaje

Originální název

Targeted Proteomics Driven Verification of Biomarker Candidates Associated with Breast Cancer Aggressiveness

Autoři

PROCHÁZKOVÁ, Iva; Juraj LENČO a Pavel BOUCHAL

Vydání

New York, Tissue Proteomics, od s. 177-184, 8 s. Methods in Molecular Biology 1788, 2018

Nakladatel

Humana Press

Další údaje

Jazyk

angličtina

Typ výsledku

Kapitola resp. kapitoly v odborné knize

Obor

10609 Biochemical research methods

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Forma vydání

tištěná verze "print"

Odkazy

URL

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14310/18:00101544

Organizační jednotka

Přírodovědecká fakulta

ISBN

978-1-4939-7852-6

Klíčová slova anglicky

Breast cancer; mTRAQ; Selected reaction monitoring

Štítky

H19, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 24. 1. 2022 11:38, Mgr. Marie Novosadová Šípková, DiS.

Anotace

V originále

Breast cancer is the most common and molecularly well-characterized malignant cancer in women; however, its progression to metastatic cancer remains lethal for 78% of patients within 5 years of diagnosis. Identifying novel markers in high risk patients using quantitative methods is essential to overcome genetic, inter-tumor, and intra-tumor variability, and to translate novel findings into cancer diagnosis and treatment. Using untargeted proteomics, we recently identified 13 proteins associated with some key factors of breast cancer aggressiveness: estrogen receptors, tumor grade, and lymph node status. Here we verified these findings in a set of 96 tumors using targeted proteomics based on selected reaction monitoring with mTRAQ labeling (mTRAQ-SRM). This study highlights a panel of gene products that could contribute to breast cancer aggressiveness and metastasis, and can help develop more precise breast cancer treatments.

Návaznosti

GA17-05957S, projekt VaV

Název: Evaluace nových potenciálních cílů a inhibitorů pro blokování vývoje metastáz u luminálních A nádorů prsu

Investor: Grantová agentura ČR, Evaluace nových potenciálních cílů a inhibitorů pro blokování vývoje metastáz u luminálních A nádorů prsu

MUNI/A/1100/2017, interní kód MU

Název: Podpora biochemického výzkumu v roce 2018

Investor: Masarykova univerzita, Podpora biochemického výzkumu v roce 2018, DO R. 2020_Kategorie A - Specifický výzkum - Studentské výzkumné projekty

Citovat

PROCHÁZKOVÁ, Iva; Juraj LENČO a Pavel BOUCHAL. Targeted Proteomics Driven Verification of Biomarker Candidates Associated with Breast Cancer Aggressiveness. In Minnie M. Sarwal and Tara K. Sigdel. Tissue Proteomics. New York: Humana Press, 2018, s. 177-184. Methods in Molecular Biology 1788. ISBN 978-1-4939-7852-6. Dostupné z: https://doi.org/10.1007/7651_2017_111.

@inbook{1484767,
   author = {Procházková, Iva and Lenčo, Juraj and Bouchal, Pavel},
   address = {New York},
   booktitle = {Tissue Proteomics},
   doi = {https://doi.org/10.1007/7651_2017_111},
   editor = {Minnie M. Sarwal and Tara K. Sigdel},
   keywords = {Breast cancer; mTRAQ; Selected reaction monitoring},
   howpublished = {tištěná verze "print"},
   language = {eng},
   location = {New York},
   isbn = {978-1-4939-7852-6},
   pages = {177-184},
   publisher = {Humana Press},
   title = {Targeted Proteomics Driven Verification of Biomarker Candidates Associated with Breast Cancer Aggressiveness},
   url = {https://link.springer.com/protocol/10.1007%2F7651_2017_111},
   year = {2018}
}

TY  - CHAP
ID  - 1484767
AU  - Procházková, Iva - Lenčo, Juraj - Bouchal, Pavel
PY  - 2018
TI  - Targeted Proteomics Driven Verification of Biomarker Candidates Associated with Breast Cancer Aggressiveness
VL  - Methods in Molecular Biology 1788
PB  - Humana Press
CY  - New York
SN  - 9781493978526
KW  - Breast cancer
KW  - mTRAQ
KW  - Selected reaction monitoring
UR  - https://link.springer.com/protocol/10.1007%2F7651_2017_111
N2  - Breast cancer is the most common and molecularly well-characterized malignant cancer in women; however, its progression to metastatic cancer remains lethal for 78% of patients within 5 years of diagnosis. Identifying novel markers in high risk patients using quantitative methods is essential to overcome genetic, inter-tumor, and intra-tumor variability, and to translate novel findings into cancer diagnosis and treatment. Using untargeted proteomics, we recently identified 13 proteins associated with some key factors of breast cancer aggressiveness: estrogen receptors, tumor grade, and lymph node status. Here we verified these findings in a set of 96 tumors using targeted proteomics based on selected reaction monitoring with mTRAQ labeling (mTRAQ-SRM). This study highlights a panel of gene products that could contribute to breast cancer aggressiveness and metastasis, and can help develop more precise breast cancer treatments.
ER  -

PROCHÁZKOVÁ, Iva; Juraj LENČO a Pavel BOUCHAL. Targeted Proteomics Driven Verification of Biomarker Candidates Associated with Breast Cancer Aggressiveness. In Minnie M. Sarwal and Tara K. Sigdel. \textit{Tissue Proteomics}. New York: Humana Press, 2018, s.~177-184. Methods in Molecular Biology 1788. ISBN~978-1-4939-7852-6. Dostupné z: https://doi.org/10.1007/7651\_{}2017\_{}111.

Přehled o publikaci